Skip to main content

The RheumNow Week in Review – 28 April 2017

Apr 30, 2017 3:14 pm

Dr. Jack Cush reviews the news from the last week on - from the ACR SOTA 2017 meeting in Chicago:

  1. ACR abstracts open for submission; Deadline date is June 19; Late breaker deadline is Sept 26. Mark Ur Calendar!
  2. Congratulations to Dr Jim O'Dell, elected by the ACP as an ACP Masterfor extraordinary career in medicine
  3. EU CHMP recommends the anti-IL6 drug sarilumab (Kevzara; Sanofi) for approval/use in RA. EMA decision awaited.
  4. Sandoz biosimilars of Enbrel and Rituxan were recommened by CHMP for approval/use in the EU. EMA decision awaited
  5. FDA Approves Renflexis as Second Infliximab Biosimilar
  6. BSR meeting reports study of 19,162 pts on a biologic shows risk of opportunistic infections to b 1/1000 over 5+yrs
  7. NPF Medical Board review says DMARDs (MTX, CyA,TNFi) can be continued perioperatively in Pso/PsA w/ low risk surgery
  8. 136 pt study; Flares in pregnancy seen in 29% RA & 25% axSpA, 3fold risk if TNFi stopd. Flares mostly Rx w/ Steroids
  9. Noninfectious clinically isolated Aortitis may be presentation of GCA, IgG4-related Dz, infectious aortitis or GPA
  10. WHO study of 31 countries shows RA mortality rates declined 48% from 1987-2011; 7.1 to 3.7/mil-years 1987 fo 2009-11
  11. Elimination of Senescent Chondrocytes Reduces Post-Traumatic Osteoarthritis 
  12. Best to Rehab at Home Following Joint Replacement
  13. Pregnancy Flares in RA and Spondylitis   


The author has received compensation as an advisor or consultant on this subject

Add new comment

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.